Myriad Genetics (MYGN)
Myriad Genetics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as in vitro & in vivo diagnostic substances.
8.5M
Short interest
settlement 2026-09-30
4.3
Days to cover
unchanged vs prior
40.0%
Short share of volume
2026-10-12
682
Fails to deliver
settlement 2026-09-10
Mon 2 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-12.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in MYGN is 8,546,169 shares, up 702,070 shares over the last month. Over the last 48 readings it ranged from 3,349,808 shares (13 December 2024) to 11,699,529 shares (13 March 2026). At the reported average volume of 2.0M shares a day that is 4.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/mygn" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 8,546,169 | -8.6% | 2,009,092 | 4.25 |
| 2026-09-15 | 9,345,601 | +19.1% | 2,190,334 | 4.27 |
| 2026-08-31 | 7,844,099 | +2.1% | 1,568,848 | 5.00 |
| 2026-08-14 | 7,682,628 | -9.6% | 2,591,093 | 2.97 |
| 2026-07-31 | 8,496,114 | +6.1% | 2,171,451 | 3.91 |
| 2026-07-15 | 8,009,903 | -6.5% | 1,094,024 | 7.32 |
| 2026-06-30 | 8,563,849 | -1.0% | 1,959,490 | 4.37 |
| 2026-06-15 | 8,650,804 | +1.1% | 1,507,111 | 5.74 |
| 2026-05-29 | 8,552,791 | +2.7% | 2,018,120 | 4.24 |
| 2026-05-15 | 8,328,878 | +5.7% | 2,191,220 | 3.80 |
| 2026-04-30 | 7,883,496 | -4.3% | 941,768 | 8.37 |
| 2026-04-15 | 8,239,658 | -6.0% | 1,040,611 | 7.92 |
| 2026-03-31 | 8,763,576 | -25.1% | 2,980,202 | 2.94 |
| 2026-03-13 | 11,699,529 | +0.6% | 2,020,421 | 5.79 |
| 2026-02-27 | 11,625,293 | +7.9% | 1,620,469 | 7.17 |
| 2026-02-13 | 10,776,200 | +1.1% | 1,040,394 | 10.36 |
| 2026-01-30 | 10,659,674 | +3.3% | 900,286 | 11.84 |
| 2026-01-15 | 10,320,998 | +7.1% | 915,204 | 11.28 |
| 2025-12-31 | 9,635,344 | +11.7% | 922,704 | 10.44 |
| 2025-12-15 | 8,629,605 | +0.7% | 900,530 | 9.58 |
| 2025-11-28 | 8,565,850 | +11.3% | 1,295,543 | 6.61 |
| 2025-11-14 | 7,694,493 | +7.4% | 1,414,205 | 5.44 |
| 2025-10-31 | 7,163,949 | -7.7% | 853,107 | 8.40 |
| 2025-10-15 | 7,761,944 | -0.3% | 974,455 | 7.97 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 12 October 2026, the short share of MYGN volume is 40.0%, up 21.2 points over the last five sessions. Over the last 30 readings it ranged from 18.7% (21 September 2026) to 74.1% (10 September 2026). The latest reading is 5.0 points above the 30-session average of 35.0%, on 389K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-12 | 155K | 389K | 40.0% | 0 |
| 2026-10-09 | 168K | 419K | 40.0% | 0 |
| 2026-10-08 | 278K | 466K | 59.7% | 0 |
| 2026-10-07 | 126K | 443K | 28.4% | 0 |
| 2026-10-06 | 198K | 536K | 36.9% | 400 |
| 2026-10-05 | 130K | 694K | 18.7% | 9,300 |
| 2026-10-02 | 231K | 844K | 27.4% | 0 |
| 2026-10-01 | 148K | 525K | 28.2% | 0 |
| 2026-09-30 | 122K | 360K | 33.8% | 0 |
| 2026-09-29 | 133K | 633K | 21.0% | 0 |
| 2026-09-28 | 126K | 439K | 28.6% | 0 |
| 2026-09-25 | 222K | 537K | 41.4% | 0 |
| 2026-09-24 | 208K | 534K | 39.0% | 0 |
| 2026-09-23 | 134K | 498K | 27.0% | 0 |
| 2026-09-22 | 214K | 951K | 22.5% | 0 |
| 2026-09-21 | 114K | 610K | 18.7% | 1,600 |
| 2026-09-18 | 241K | 1.1M | 21.0% | 0 |
| 2026-09-17 | 421K | 1.3M | 33.4% | 0 |
| 2026-09-16 | 160K | 653K | 24.5% | 0 |
| 2026-09-15 | 392K | 1.9M | 20.9% | 0 |
| 2026-09-14 | 402K | 1.0M | 39.8% | 5,100 |
| 2026-09-11 | 289K | 974K | 29.7% | 0 |
| 2026-09-10 | 1.6M | 2.1M | 74.1% | 5 |
| 2026-09-09 | 173K | 336K | 51.5% | 0 |
| 2026-09-08 | 153K | 394K | 38.7% | 0 |
| 2026-09-04 | 98K | 258K | 38.1% | 0 |
| 2026-09-03 | 95K | 294K | 32.3% | 0 |
| 2026-09-02 | 164K | 430K | 38.2% | 0 |
| 2026-09-01 | 700K | 1.2M | 59.6% | 0 |
| 2026-08-31 | 151K | 407K | 37.0% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 10 September 2026, the fails-to-deliver balance in MYGN is 682 shares, up 664 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (19 August 2026) to 10,727 shares (17 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-10 | 682 | $3.19 | $2K |
| 2026-09-02 | 18 | $3.18 | $57 |
| 2026-08-25 | 607 | $3.05 | $2K |
| 2026-08-19 | 2 | $2.87 | $6 |
| 2026-08-14 | 14 | $3.17 | $44 |
| 2026-08-11 | 37 | $3.25 | $120 |
| 2026-07-29 | 25 | $5.32 | $133 |
| 2026-07-17 | 10,727 | $6.19 | $66K |
| 2026-07-16 | 605 | $6.31 | $4K |
| 2026-07-14 | 3,484 | $5.86 | $20K |
| 2026-07-09 | 5,632 | $5.87 | $33K |
| 2026-07-08 | 5,591 | $5.86 | $33K |
| 2026-07-07 | 3,962 | $6.03 | $24K |
| 2026-06-30 | 9,849 | $5.85 | $58K |
| 2026-06-17 | 4,040 | $4.25 | $17K |
| 2026-06-15 | 87 | $4.33 | $377 |
| 2026-06-11 | 520 | $4.43 | $2K |
| 2026-06-03 | 118 | $4.31 | $509 |
| 2026-05-01 | 43 | $4.75 | $204 |
| 2026-04-09 | 1,990 | $4.77 | $9K |
| 2026-03-24 | 719 | $4.66 | $3K |
| 2026-03-23 | 2,810 | $4.58 | $13K |
| 2026-03-20 | 9 | $4.75 | $43 |
| 2026-03-19 | 1,509 | $4.64 | $7K |
| 2026-03-13 | 297 | $4.85 | $1K |
| 2026-03-04 | 117 | $5.29 | $619 |
| 2026-02-24 | 2,000 | $4.38 | $9K |
| 2026-02-13 | 57 | $4.53 | $258 |
| 2025-12-22 | 30 | $6.55 | $197 |
| 2025-11-06 | 30 | $6.58 | $197 |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONNo open-market insider trades were reported for MYGN in the last 90 days. The most recent filings are listed below. Latest filing: Wheeler Benjamin Richard (Chief Financial Officer) on 2026-09-21.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-21 | Wheeler Benjamin Richard | Chief Financial Officer | Tax withholding | 3K | $4.01 | $10K | 287K |
| 2026-09-16 | Sikri Vishal | EVP, Commercial | Grant | 258K | $0.00 | $0 | 351K |
| 2026-09-03 | Fox Jennifer Lynne | Chief Legal Officer | Tax withholding | 4K | $3.23 | $14K | 306K |
| 2026-08-16 | Wheeler Benjamin Richard | Chief Financial Officer | Tax withholding | 9K | $3.03 | $27K | 290K |
| 2026-06-11 | Donnelly Brian J | Chief Commerical Officer | Grant | 5K | $3.94 | $20K | 573K |
| 2026-06-11 | Raha Samraat S. | President and CEO | Grant | 4K | $3.94 | $14K | 1.1M |
| 2026-06-08 | Kumar Rashmi | Director | Sell | 15K | $4.46 | $67K | 172K |
| 2026-06-04 | Newcomer Lee Nisley | Director | Grant | 60K | $0.00 | $0 | 192K |
| 2026-06-04 | Reitan Colleen F | Director | Grant | 60K | $0.00 | $0 | 152K |
| 2026-06-04 | Skovronsky Daniel | Director | Grant | 60K | $0.00 | $0 | 196K |
| 2026-06-04 | Phanstiel S. Louise | Director | Grant | 60K | $0.00 | $0 | 342K |
| 2026-06-04 | Kumar Rashmi | Director | Grant | 60K | $0.00 | $0 | 187K |
| 2026-06-04 | Dreismann Heinrich | Director | Grant | 60K | $0.00 | $0 | 231K |
| 2026-06-04 | Davis Mark Steven | Director | Grant | 60K | $0.00 | $0 | 107K |
| 2026-06-04 | Bisaro Paul | Director | Grant | 60K | $0.00 | $0 | 157K |
| 2026-06-01 | Jampa Raj | Chief Technology Officer | Grant | 252K | $0.00 | $0 | 252K |
| 2026-05-14 | Bisaro Paul | Director | Buy | 8K | $3.69 | $28K | 97K |
| 2026-05-01 | Donnelly Brian J | Chief Commerical Officer | Tax withholding | 56K | $4.80 | $269K | 568K |
| 2026-04-14 | Muzzey Dale | Chief Scientific Officer | Tax withholding | 946 | $4.91 | $5K | 326K |
| 2026-04-14 | Verratti Mark | Chief Operating Officer | Tax withholding | 1K | $4.91 | $5K | 630K |
| 2026-03-22 | Wheeler Benjamin Richard | Chief Financial Officer | Tax withholding | 549 | $4.58 | $3K | 299K |
| 2026-03-22 | Muzzey Dale | Chief Scientific Officer | Tax withholding | 2K | $4.58 | $9K | 327K |
| 2026-03-22 | Verratti Mark | Chief Operating Officer | Tax withholding | 2K | $4.58 | $9K | 631K |
| 2026-03-15 | Wheeler Benjamin Richard | Chief Financial Officer | Tax withholding | 2K | $4.66 | $10K | 299K |
| 2026-03-15 | Wheeler Benjamin Richard | Chief Financial Officer | Tax withholding | 877 | $4.66 | $4K | 301K |
| 2026-03-15 | Muzzey Dale | Chief Scientific Officer | Tax withholding | 12K | $4.66 | $56K | 329K |
| 2026-03-15 | Muzzey Dale | Chief Scientific Officer | Tax withholding | 5K | $4.66 | $22K | 341K |
| 2026-03-15 | Verratti Mark | Chief Operating Officer | Tax withholding | 9K | $4.66 | $42K | 633K |
| 2026-03-15 | Verratti Mark | Chief Operating Officer | Tax withholding | 6K | $4.66 | $26K | 642K |
| 2026-03-15 | Haas Kevin Richard | Chief Technology Officer | Tax withholding | 8K | $4.66 | $39K | 180K |
| 2026-03-15 | Haas Kevin Richard | Chief Technology Officer | Tax withholding | 3K | $4.66 | $16K | 188K |
| 2026-03-14 | Wheeler Benjamin Richard | Chief Financial Officer | Tax withholding | 1K | $4.66 | $5K | 302K |
| 2026-03-14 | Muzzey Dale | Chief Scientific Officer | Tax withholding | 8K | $4.66 | $39K | 346K |
| 2026-03-14 | Raha Samraat S. | President and CEO | Tax withholding | 11K | $4.66 | $50K | 1.1M |
| 2026-03-14 | Verratti Mark | Chief Operating Officer | Tax withholding | 5K | $4.66 | $25K | 647K |
| 2026-03-14 | Solaiman Shereen | Chief People Officer | Tax withholding | 6K | $4.66 | $27K | 268K |
| 2026-03-14 | Haas Kevin Richard | Chief Technology Officer | Tax withholding | 4K | $4.66 | $19K | 192K |
| 2026-03-13 | Wheeler Benjamin Richard | Chief Financial Officer | Tax withholding | 586 | $4.66 | $3K | 303K |
| 2026-03-13 | Muzzey Dale | Chief Scientific Officer | Tax withholding | 13K | $4.66 | $60K | 354K |
| 2026-03-13 | Raha Samraat S. | President and CEO | Tax withholding | 36K | $4.66 | $169K | 1.1M |
| 2026-03-13 | Verratti Mark | Chief Operating Officer | Tax withholding | 9K | $4.66 | $43K | 653K |
| 2026-03-13 | Solaiman Shereen | Chief People Officer | Tax withholding | 9K | $4.66 | $41K | 274K |
| 2026-03-13 | Haas Kevin Richard | Chief Technology Officer | Tax withholding | 6K | $4.66 | $30K | 196K |
| 2026-03-13 | Fox Jennifer Lynne | Chief Legal Officer | Tax withholding | 6K | $4.66 | $28K | 310K |
| 2026-03-12 | Wheeler Benjamin Richard | Chief Financial Officer | Grant | 206K | $0.00 | $0 | 304K |
| 2026-03-12 | Muzzey Dale | Chief Scientific Officer | Grant | 173K | $0.00 | $0 | 367K |
| 2026-03-12 | Raha Samraat S. | President and CEO | Grant | 619K | $0.00 | $0 | 1.1M |
| 2026-03-12 | Verratti Mark | Chief Operating Officer | Grant | 247K | $0.00 | $0 | 662K |
| 2026-03-12 | Solaiman Shereen | Chief People Officer | Grant | 173K | $0.00 | $0 | 282K |
| 2026-03-12 | Fox Jennifer Lynne | Chief Legal Officer | Grant | 196K | $0.00 | $0 | 316K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON1 Form 144 notice on file for MYGN worth $69K at the prices reported; 0 in the last 90 days worth $0. Latest: Kumar Rashmi filed on 2026-06-08 to sell 15,000 shares ($69K) from 2026-06-08.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-06-08 | Kumar RashmiDirector | 15K | $69K | 0.016% | 2026-06-08 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON9 holders report 5% or more of MYGN in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock Portfolio Management LLC at 10.4% of the class (9,900,937 shares), filed 2026-09-04 for an event on 2026-08-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-09-04 | 13G | BlackRock Portfolio Management LLCparent holding company | 9.9M | 10.4% | 2026-08-31 |
| 2026-08-14 | 13G/Ano. 1 | GLENVIEW CAPITAL MANAGEMENT, LLCother entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | ROBBINS LARRYindividual, parent holding company | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G | Vestal Point Capital, LPinvestment adviser, partnership | 5.7M | 6.1% | 2026-06-30 |
| 2026-08-14 | 13G | Ryan Wilderparent holding company, individual | 5.7M | 6.1% | 2026-06-30 |
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 5.0M | 5.3% | 2026-06-30 |
| 2026-04-07 | 13G/Ano. 5 | BlackRock, Inc.parent holding company | 8.0M | 8.5% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 14 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-11 | 13G/Ano. 3 | Millennium Group Management LLCother entity | 6.7M | 7.2% | 2025-12-31 |
| 2026-02-11 | 13G/Ano. 3 | Millennium Management LLCother entity | 6.7M | 7.2% | 2025-12-31 |
| 2026-02-11 | 13G/Ano. 3 | Israel A. Englanderindividual | 6.7M | 7.2% | 2025-12-31 |
| 2026-02-11 | 13G/Ano. 3 | Integrated Core Strategies (US) LLCother entity | 5.2M | 5.6% | 2025-12-31 |
| 2025-11-12 | 13G/Ano. 1 | Barclays PLCparent holding company | 3.9M | 4.2% | 2025-09-30 |
13F holders
Tracked managers holding MYGN at their latest 13F. JSON6 of the 30 tracked managers held MYGN at their latest 13F, $98.8M in total at quarter-end prices. Millennium Management is the largest at $37.8M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 6.6M | $37.8M | 0.01% | -48K |
| D. E. Shaw & Co. | 2026-06-30 | 4.6M | $26.2M | 0.01% | +82K |
| AQR Capital Management | 2026-06-30 | 2.8M | $15.8M | 0.01% | +854K |
| Two Sigma Investments | 2026-06-30 | 1.6M | $8.9M | 0.01% | +274K |
| Citadel Advisors | 2026-06-30 | 1.5M | $8.8M | 0.00% | +1.1M |
| Point72 Asset Management | 2026-06-30 | 239K | $1.4M | 0.00% | -719K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Myriad Genetics reported revenue of $190.7M, down 10.5% from the same quarter a year earlier, and net loss of $43.2M (-0.46 diluted EPS). In FY 2025 it generated $1.8M of operating cash flow. As of 2026-06-30, cash was $115.2M against $120.7M of debt.
- Cash
- $115.2M
- Debt
- $120.7M
- Equity
- $303.9M
- Total assets
- $638.9M
- Shares outstanding
- 95,649,645
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $190.7M | -$43.2M | -22.7% | -0.46 |
| Q1 FY 2026 | 2026-03-31 | $200.4M | -$34.1M | -17.0% | -0.36 |
| Q4 FY 2025derived | 2025-12-31 | $209.8M | -$7.9M | -3.8% | n/a |
| Q3 FY 2025 | 2025-09-30 | $205.7M | -$27.4M | -13.3% | -0.29 |
| Q2 FY 2025 | 2025-06-30 | $213.1M | -$330.5M | -155.1% | -3.57 |
| Q1 FY 2025 | 2025-03-31 | $195.9M | -$100K | -0.1% | 0.00 |
| Q4 FY 2024derived | 2024-12-31 | $210.6M | -$42.5M | -20.2% | n/a |
| Q3 FY 2024 | 2024-09-30 | $213.3M | -$22.1M | -10.4% | -0.24 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $824.5M | -$365.9M | $1.8M | n/a | n/a | n/a |
| FY 2024 | 2024-12-31 | $837.6M | -$127.3M | -$8.7M | n/a | n/a | n/a |
| FY 2023 | 2023-12-31 | $753.2M | -$263.3M | -$110.9M | n/a | n/a | n/a |
| FY 2022 | 2022-12-31 | $678.4M | -$112.0M | -$106.3M | $45.3M | n/a | n/a |
| FY 2021 | 2021-12-31 | $690.6M | -$27.2M | $18.6M | $18.0M | $0 | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-28 from the cover page.
What this page is
Myriad Genetics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Myriad Genetics (MYGN), SEC CIK 899923, listed on Nasdaq, classified by the SEC as in vitro & in vivo diagnostic substances. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-12.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-10.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-06-08.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-09-04.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-07-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-21.JSON and CSV
- Company record
- EDGAR filing index for CIK 899923Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as in vitro & in vivo diagnostic substances
Other company pages
Datasets
Frequently Asked Questions
How much of MYGN is sold short?
What is MYGN's daily short volume?
Does MYGN have fails to deliver?
Are MYGN insiders buying or selling?
Have MYGN insiders filed to sell?
Who owns 5% or more of MYGN?
What did MYGN report last quarter?
Which tracked 13F managers own MYGN?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.